Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Circassia Pharmaceuticals plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Circassia Pharmaceuticals plc - Product Pipeline Review - 2014', provides an overview of the Circassia Pharmaceuticals plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Circassia Pharmaceuticals plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Circassia Pharmaceuticals plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Circassia Pharmaceuticals plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Circassia Pharmaceuticals plc's pipeline products Reasons to buy - Evaluate Circassia Pharmaceuticals plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Circassia Pharmaceuticals plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Circassia Pharmaceuticals plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Circassia Pharmaceuticals plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Circassia Pharmaceuticals plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Circassia Pharmaceuticals plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Circassia Pharmaceuticals plc Snapshot 5 Circassia Pharmaceuticals plc Overview 5 Key Information 5 Key Facts 5 Circassia Pharmaceuticals plc - Research and Development Overview 6 Key Therapeutic Areas 6 Circassia Pharmaceuticals plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Circassia Pharmaceuticals plc - Pipeline Products Glance 10 Circassia Pharmaceuticals plc - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Circassia Pharmaceuticals plc - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Circassia Pharmaceuticals plc - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Circassia Pharmaceuticals plc - Drug Profiles 15 Cat-SPIRE 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Grass-SPIRE 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 House Dust Mite-SPIRE 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Ragweed-SPIRE 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CIR-001 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ToleroMune Birch Allergy T-Cell Vaccine 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ToleroMune Alternaria Allergy T-Cell Vaccines 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ToleroMune Japanese Cedar Allergy T Cell Vaccine 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Circassia Pharmaceuticals plc - Pipeline Analysis 28 Circassia Pharmaceuticals plc - Pipeline Products by Target 28 Circassia Pharmaceuticals plc - Pipeline Products by Route of Administration 29 Circassia Pharmaceuticals plc - Pipeline Products by Molecule Type 30 Circassia Pharmaceuticals plc - Pipeline Products by Mechanism of Action 31 Circassia Pharmaceuticals plc - Recent Pipeline Updates 32 Circassia Pharmaceuticals plc - Dormant Projects 36 Circassia Pharmaceuticals plc - Locations And Subsidiaries 37 Head Office 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Circassia Pharmaceuticals plc, Key Information 5 Circassia Pharmaceuticals plc, Key Facts 5 Circassia Pharmaceuticals plc - Pipeline by Indication, 2014 7 Circassia Pharmaceuticals plc - Pipeline by Stage of Development, 2014 8 Circassia Pharmaceuticals plc - Monotherapy Products in Pipeline, 2014 9 Circassia Pharmaceuticals plc - Phase III, 2014 10 Circassia Pharmaceuticals plc - Phase II, 2014 11 Circassia Pharmaceuticals plc - Phase I, 2014 12 Circassia Pharmaceuticals plc - Preclinical, 2014 13 Circassia Pharmaceuticals plc - Discovery, 2014 14 Circassia Pharmaceuticals plc - Pipeline by Target, 2014 28 Circassia Pharmaceuticals plc - Pipeline by Route of Administration, 2014 29 Circassia Pharmaceuticals plc - Pipeline by Molecule Type, 2014 30 Circassia Pharmaceuticals plc - Pipeline Products by Mechanism of Action, 2014 31 Circassia Pharmaceuticals plc - Recent Pipeline Updates, 2014 32 Circassia Pharmaceuticals plc - Dormant Developmental Projects,2014 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.